Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

Mersana Therapeutics, Inc.

(Name of Issuer)

 

Common stock, $0.0001 par value per share

(Title of Class of Securities)

 

59045L106

(CUSIP Number)

 

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

	¨	Rule 13d-1(b)
	x	Rule 13d-1(c)
	¨	Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No.   59045L106
1.	Names of Reporting Persons   Nextech Crossover I SCSp
2.	Check the Appropriate Box if a Member of a Group (See Instructions)   (a) ¨     (b) x (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization   Luxembourg

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power   12,067,246 shares
	6.	Shared Voting Power   0
	7.	Sole Dispositive Power   12,067,246 shares
	8.	Shared Dispositive Power   0

9.	Aggregate Amount Beneficially Owned by Each Reporting Person   12,067,246 shares
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
11.	Percent of Class Represented by Amount in Row (9)   9.8% (2)
12.	Type of Reporting Person (See Instructions)   PN

 

(1)

This Schedule 13G is filed by Nextech Crossover I SCSP (“Nextech Crossover LP”), Nextech Crossover I GP S.à r.l. (“Nextech Crossover GP”), Ian Charoub, (“Charoub”), Costas Constantinides (“Constantinides”) and Rocco Sgobbo (“Sgobbo” and, with Nextech Crossover LP, Nextech Crossover GP, Charoub and Constantinides, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)

The percent of class was calculated based on 122,675,051 shares of Common Stock outstanding as of August 9, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 13, 2024.

 

2

 

CUSIP No.   59045L106
1.	Names of Reporting Persons   Nextech Crossover I GP S.à r.l.
2.	Check the Appropriate Box if a Member of a Group (See Instructions)   (a) ¨     (b) x (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization   Luxembourg

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power   12,067,246 shares
	6.	Shared Voting Power   0
	7.	Sole Dispositive Power   12,067,246 shares
	8.	Shared Dispositive Power   0

9.	Aggregate Amount Beneficially Owned by Each Reporting Person   12,067,246 shares
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
11.	Percent of Class Represented by Amount in Row (9)   9.8% (2)
12.	Type of Reporting Person (See Instructions)   OO

 

(1)

This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)

The percent of class was calculated based on 122,675,051 shares of Common Stock outstanding as of August 9, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

 

3

 

CUSIP No.   59045L106
1.	Names of Reporting Persons   Ian Charoub
2.	Check the Appropriate Box if a Member of a Group (See Instructions)   (a) ¨     (b) x (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization   Sweden

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power   0
	6.	Shared Voting Power   12,067,246 shares
	7.	Sole Dispositive Power   0
	8.	Shared Dispositive Power   12,067,246 shares

9.	Aggregate Amount Beneficially Owned by Each Reporting Person   12,067,246 shares
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
11.	Percent of Class Represented by Amount in Row (9)   9.8% (2)
12.	Type of Reporting Person (See Instructions)   IN

 

(1)

This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)

The percent of class was calculated based on 122,675,051 shares of Common Stock outstanding as of August 9, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

 

4

 

CUSIP No.   59045L106
1.	Names of Reporting Persons   Costas Constantinides
2.	Check the Appropriate Box if a Member of a Group (See Instructions)   (a) ¨     (b)  x (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization   Cyprus

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power   0
	6.	Shared Voting Power   12,067,246 shares
	7.	Sole Dispositive Power   0
	8.	Shared Dispositive Power   12,067,246 shares

9.	Aggregate Amount Beneficially Owned by Each Reporting Person   12,067,246 shares
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
11.	Percent of Class Represented by Amount in Row (9)   9.8% (2)
12.	Type of Reporting Person (See Instructions)   IN

 

(1)

This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)

The percent of class was calculated based on 122,675,051 shares of Common Stock outstanding as of August 9, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

 

5

 

CUSIP No.   59045L106
1.	Names of Reporting Persons   Rocco Sgobbo
2.	Check the Appropriate Box if a Member of a Group (See Instructions)   (a) ¨     (b) x (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization   Switzerland

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power   0
	6.	Shared Voting Power   12,067,246 shares
	7.	Sole Dispositive Power   0
	8.	Shared Dispositive Power   12,067,246 shares

9.	Aggregate Amount Beneficially Owned by Each Reporting Person   12,067,246 shares
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
11.	Percent of Class Represented by Amount in Row (9)   9.8% (2)
12.	Type of Reporting Person (See Instructions)   IN

 

(1)

This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)

The percent of class was calculated based on 122,675,051 shares of Common Stock outstanding as of August 9, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

 

6

 

Item 1.
	(a)	Name of Issuer   Mersana Therapeutics, Inc.
	(b)	Address of Issuer’s Principal Executive Offices   840 Memorial Drive Cambridge, MA 02139
Item 2.
	(a)	Name of Person Filing   Nextech Crossover I SCSp (“Nextech Crossover LP”) Nextech Crossover I GP S.à r.l. (“Nextech Crossover GP”) Ian Charoub (“Charoub”) Costas Constantinides (“Constantinides”) Rocco Sgobbo (“Sgobbo”)
	(b)	Address of Principal Business Office or, if none, Residence   8 rue Lou Hemmer L-1748 Luxembourg-Findel Grand-Duché de Luxembourg

	(c)	Citizenship
		Name	Citizenship or Place of Organization
		Nextech Crossover LP	Luxembourg
		Nextech Crossover GP	Luxembourg
		Charoub	Sweden
		Constantinides	Cyprus
		Sgobbo	Switzerland

	(d)	Title of Class of Securities   Common Stock, $0.0001 par value (“Common Stock”)
	(e)	CUSIP Number   59045L106
Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
	Not applicable

 

7

 

Item 4.

Ownership

 

The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of November 14, 2024:

 

Reporting Persons		Shares Held Directly				Sole Voting Power				Shared Voting Power				Sole Dispositive Power				Shared Dispositive Power				Beneficial Ownership				Percentage of Class (2)
Nextech Crossover LP (1)			12,067,246				12,067,246								12,067,246								12,067,246				9.8	%
Nextech Crossover GP (1)							12,067,246								12,067,246								12,067,246				9.8	%
Charoub (1)											12,067,246								12,067,246				12,067,246				9.8	%
Constantinides (1)											12,067,246								12,067,246				12,067,246				9.8	%
Sgobbo (1)											12,067,246								12,067,246				12,067,246				9.8	%

 

(1)

The shares are held by Nextech Crossover LP. Nextech Crossover GP serves as the sole general partner of Nextech Crossover LP and has sole voting and investment control over the shares owned by Nextech Crossover LP and may be deemed to own beneficially the shares held by Nextech Crossover LP. Nextech Crossover GP owns no securities of the Issuer directly. Charoub, Constantinides and Sgobbo are members of the board of managers of Nextech Crossover GP and share voting and dispositive power over the shares held by Nextech Crossover LP, and may be deemed to own beneficially the shares held by Nextech Crossover LP. Charoub, Constantinides and Sgobbo own no securities of the Issuer directly.

(2)

The percent of class was calculated based on 122,675,051 shares of Common Stock outstanding as of August 9, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

 

Item 5.	Ownership of Five Percent or Less of a Class
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨

 

Item 6.	Ownership of More than Five Percent on Behalf of Another Person
	Not applicable

 

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
	Not applicable

 

Item 8.	Identification and Classification of Members of the Group
	Not applicable

 

Item 9.	Notice of Dissolution of Group
	Not applicable

 

Item 10.	Certification
	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

 

8

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: November 14, 2024

 

Nextech Crossover I SCSp
By:	Nextech Crossover I GP S.à r.l.
its	General Partner

 

By:	/s/ Ian Charoub
	Name:	Ian Charoub
	Title:	Manager
By:	/s/ Costas Constantinides
	Name:	Costas Constantinides
	Title:	Manager

 

Nextech Crossover I GP S.à r.l.
By:	/s/ Ian Charoub
	Name:	Ian Charoub
	Title:	Manager
By:	/s/ Costas Constantinides
	Name:	Costas Constantinides
	Title:	Manager
/s/ Ian Charoub
Ian Charoub
/s/ Costas Constantinides
Costas Constantinides
/s/ Rocco Sgobbo
Rocco Sgobbo

 

	ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

 

9

 

Exhibit(s):

 

A

Joint Filing Agreement

 

10

 

EXHIBIT A

 

JOINT FILING AGREEMENT

 

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Mersana Therapeutics, Inc. is filed on behalf of each of us.

 

Dated: November 14, 2024

 

Nextech Crossover I SCSp
By:	Nextech Crossover I GP S.à r.l.
its	General Partner

 

By:	/s/ Ian Charoub
	Name:	Ian Charoub
	Title:	Manager
By:	/s/ Costas Constantinides
	Name:	Costas Constantinides
	Title:	Manager

 

Nextech Crossover I GP S.à r.l.
By:	/s/ Ian Charoub
	Name:	Ian Charoub
	Title:	Manager
By:	/s/ Costas Constantinides
	Name:	Costas Constantinides
	Title:	Manager
/s/ Ian Charoub
Ian Charoub
/s/ Costas Constantinides
Costas Constantinides
/s/ Rocco Sgobbo
Rocco Sgobbo

 

 

 

---